Antibodies against EGFR and their uses
AssigneeErasca, Inc.
InventorsSachdev Sidhu, Jarrett Adams, Max London, Dewald Van Dyk
Life of this patent
Estimating the term…
Abstract
Described herein are antibodies that bind EGFR domain II and/or Domain III. Also described are bispecific antibodies that bind domain II and domain II of EGFR. Also described are methods and uses for treating cancer.
Claims21
An antibody or antigen binding fragment thereof, comprising an EGFR domain II binding moiety, wherein the EGFR domain II binding moiety comprises:
- a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in SEQ ID NO:
- 17;
- b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in SEQ ID NO:
- 18;
- c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
- 19, or 23 to 38;
- d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
- 4 or 5;
- e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence set forth in SEQ ID NO:
- 6;
- and
- f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in SEQ ID NO:
- 7.
An antibody or antigen binding fragment thereof, comprising an EGFR domain III binding moiety, wherein the EGFR domain III antigen binding moiety comprises:
- a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in SEQ ID NO:
- 52;
- b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in SEQ ID NO:
- 53;
- c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
- 54 to 60;
- d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
- 4 or 5;
- e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence set forth in SEQ ID NO:
- 6;
- and
- f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in SEQ ID NO:
- 7.
An antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof is a multispecific antibody, comprising an EGFR domain II binding moiety and an EGFR domain III binding moiety, wherein the EGFR domain II binding moiety comprises:
- a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in SEQ ID NO:
- 17;
- b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in SEQ ID NO:
- 18;
- c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
- 19, or 23 to 38;
- d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
- 4 or 5;
- e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence set forth in SEQ ID NO:
- 6;
- and
- f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in SEQ ID NO:
- 7;
- and wherein the EGFR domain III antigen binding moiety comprises:
- g) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in SEQ ID NO:
- 52;
- h) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in SEQ ID NO:
- 53;
- i) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
- 54 to 60;
- j) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
- 4 or 5;
- k) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence set forth in SEQ ID NO:
- 6;
- and
- l) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in SEQ ID NO:
- 7.
Dependencies are inferred from the claim text.